Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index; 23 of the 25 sources its claims cite were checked for support.
Abstract
Background Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events. We sought to determine whether alirocumab, a human monoclonal antibody to proprotein convertase subtilisin–kexin type 9 (PCSK9), would improve cardiovascular outcomes after an acute coronary syndrome in patients receiving high‐intensity statin therapy. Methods We conducted a multicenter, randomized, double‐blind, placebo‐controlled trial involving 18,924 patients who had an acute coronary syndrome 1 to 12 months earlier, had a low‐density lipoprotein (LDL) cholesterol level of at least 70 mg per deciliter (1.8 mmol per liter), a non‐high‐density lipoprotein cholesterol level of at least 100 mg per deciliter (2.6 mmol per liter), or an apolipoprotein B level of at least 80 mg per deciliter, and were receiving statin therapy at a high‐intensity dose or at the maximum tolerated dose. Patients were randomly assigned to receive alirocumab subcutaneously at a dose of 75 mg (9462 patients) or matching placebo (9462 patients) every 2 weeks. The dose of alirocumab was adjusted under blinded conditions to target an LDL cholesterol level of 25 to 50 mg per deciliter (0.6 to 1.3 mmol per liter). The primary end point was a composite of death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization. Results The median duration of follow‐up was 2.8 years. A composite primary end‐point e…
Overview
CoChat Summary
TL;DR
In patients with a recent acute coronary syndrome receiving high-intensity or maximum-tolerated statin therapy, alirocumab reduced the risk of recurrent ischemic cardiovascular events compared with placebo. The benefit was driven mainly by the composite primary end point, with similar adverse-event rates except for more local injection-site reactions.
Key findings
- The primary composite end point occurred in 903 patients (9.5%) in the alirocumab group vs. 1052 patients (11.1%) in the placebo group (hazard ratio, 0.85; 95% CI, 0.78 to 0.93; P<0.001); the 4-year Kaplan-Meier estimate was 12.5% vs. 14.5%, and 49 patients would need treatment for 4 years to prevent one primary event.
- Death from any cause occurred in 334 patients (3.5%) in the alirocumab group vs. 392 patients (4.1%) in the placebo group (hazard ratio, 0.85; 95% CI, 0.73 to 0.98).
- Absolute benefit was greater among patients with baseline LDL cholesterol ≥100 mg/dL; in that nonprespecified subgroup, 16 patients (95% CI, 11 to 34) would need treatment for 4 years to prevent one primary event (P<0.001 for interaction).
- Adverse events were similar between groups except local injection-site reactions, which occurred in 3.8% of alirocumab patients vs. 2.1% of placebo patients (P<0.001).
Methods
- Multicenter, randomized, double-blind, placebo-controlled trial enrolling 18,924 patients who had an acute coronary syndrome 1 to 12 months earlier and elevated atherogenic lipid levels despite high-intensity or maximum-tolerated statin therapy.
- Patients were randomly assigned 1:1 to subcutaneous alirocumab 75 mg every 2 weeks (9462 patients) or matching placebo (9462 patients), with blinded dose adjustment targeting LDL cholesterol 25 to 50 mg/dL.
- The primary end point was a composite of death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization; median follow-up was 2.8 years, with intention-to-treat Cox proportional-hazards analysis stratified by geographic region.
Limitations
- The paper states that a limitation of all three PCSK9 antibody trials, including this one, is infrequent use of ezetimibe because its cardiovascular efficacy was established after most patients had already been enrolled.
- The paper states that whether safety and efficacy were influenced by the blinded dose-adjustment strategy is unknown, and that neither this trial nor FOURIER can fully predict longer-term safety of PCSK9 monoclonal antibody treatment.
- Evident from the text: median follow-up was 2.8 years, limiting assessment of longer-term outcomes; the baseline LDL cholesterol ≥100 mg/dL subgroup finding was from a nonprespecified analysis.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
15 Valid · 1 Not valid · 3 Not checked · 54 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“These findings have led to the development of monoclonal antibodies to PCSK9 that produce substantial reductions in LDL cholesterol when administered alone or with a statin. 8-12”
What the sources say
- Supportedcites [8] 8. Stein EA, Mellis S, Yancopoulos GD, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 2012; 366: 1108-18. source
The Discussion (page not supplied) states that REGN727 lowered LDL cholesterol both alone and in subjects already receiving atorvastatin. The Lipid and Lipoprotein Response section reports substantial reductions in the atorvastatin-treated groups. (LLM, conf=0.93)
- Could not verifycites [9] 9. Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1489-99. sourceExperimental — accuracy not yet measured
The supplied copy contains repository metadata and a PDF listing, but no passage reporting LDL-cholesterol outcomes (Abstract listing). Searches for PCSK9 antibodies, alirocumab, LDL reduction, and use with or without a statin returned no matching passages. The claim therefore cannot be checked against our copy. (LLM, conf=0.78)
- Supportedcites [10] 10. Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 2014; 370: 1809-19. source
The Efficacy End Points section reports substantial LDL-cholesterol reductions with the PCSK9 monoclonal antibody evolocumab both in the diet-alone group and in groups receiving atorvastatin. The paper also describes earlier trials of PCSK9 inhibitors that significantly reduced LDL cholesterol. (LLM, conf=0.92)
- Supportedcites [11] 11. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017; 376: 1713-22. source
The Introduction (p. 1714) says PCSK9 monoclonal antibodies effectively lower LDL cholesterol and that evolocumab reduces it by approximately 60%. Its cited studies include both an anti-PCSK9 monotherapy trial and a trial adding evolocumab to statin therapy (References); the Discussion also reports a 59% reduction with statin therapy. (LLM, conf=0.88)
- Supportedcites [12] 12. Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1500-9. source
The paper describes PCSK9 monoclonal antibodies as very effective at lowering LDL cholesterol. Its End Points table includes evolocumab trials with no background lipid therapy and trials with statins; the Lipid Changes section reports a 61% LDL-cholesterol reduction with evolocumab versus standard therapy at 12 weeks. The reported reduction is pooled, not a separate estimate for each treatment setting. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events.”
What the sources say
- Partly supportedcites [1] 1. Fox KA, Goodman SG, Klein W, et al. Management of acute coronary syndromes - variations in practice and outcome; findings from the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2002; 23: 1177-89. sourceExperimental — accuracy not yet measured
The Results section (p. 1181) reports in-hospital reinfarction after acute coronary syndrome, supporting a risk of recurrent events during admission. The paper says six-month outcomes were collected (Data collection), but it does not report those results here, so it does not establish a high risk of recurrent events after discharge. (LLM, conf=0.80)
- Partly supportedcites [2] 2. Jernberg T, Hasvold P, Henriksson M, Hjelm H, Thuresson M, Janzon M. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a longterm perspective. Eur Heart J 2015; 36: 1163-70. sourceExperimental — accuracy not yet measured
The Results report an 18.3% one-year risk of MI, stroke, or cardiovascular death after an index MI, and the Discussion says risk remained high in subsequent years. This supports the claim for patients after MI, but the study does not establish the same risk for all patients after acute coronary syndrome, a broader group. (LLM, conf=0.84)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Similarly, a recent meta-analysis showed that intensive lowering of LDL cholesterol (primarily with the use of statins) resulted in a mortality benefit that was observed only among patients with a baseline LDL cholesterol level of 100 mg or more per deciliter. 20”
What the sources say
- Supportedcites [20] 20. Navarese EP, Robinson JG, Kowalewski M, et al. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and meta-analysis. JAMA 2018; 319: 1566-79. source
The All-Cause Mortality and Cardiovascular Mortality sections report mortality risk reductions with more intensive LDL-C lowering only in trials with baseline LDL-C levels of at least 100 mg/dL. The Study Selection and Patient Population section reports that 26 of the 34 trials used statin monotherapy, supporting “primarily with statins.” The threshold describes trial-level baseline LDL-C, rather than a demonstrated cutoff for individual patients. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“A limitation of all three trials is the infrequent use of ezetimibe, for which cardiovascular efficacy was established 5 after most of the patients had already been enrolled and the trials were well under way.”
What the sources say
- Supportedcites [5] 5. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015; 372: 2387-97. source
The citation is attached to the assertion that ezetimibe’s cardiovascular efficacy was established. The Conclusions report improved cardiovascular outcomes when ezetimibe was added to statin therapy, and the Efficacy End Points section reports significantly fewer cardiovascular events. The timing relative to the citing authors’ three trials is their own framing, not a finding attributed to this source. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The current trial and the FOURIER trial showed similar improvements in composite cardiovascular outcomes with PCSK9 inhibition among patients who had a baseline LDL cholesterol level of 70 mg or more per deciliter and whose average baseline LDL cholesterol level was approximately 90 mg per deciliter. 10”
What the sources say
- Partly supportedcites [10] 10. Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 2014; 370: 1809-19. sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 1 unverifiable. Expand the claim to see per-atom verdicts.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
24 more claims · 3 with their cited sources checked
Create a free account to see all 73 claims and every source verdict.
- Probably not a substantial claim. 20
- It may state two separate claims as one. 27
- The quote only partly states this claim. 4
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the cumulative data from the FOURIER and ODYSSEY OUTCOMES trials suggest that PCSK9 inhibitors effectively lower LDL-C and cardiovascular risk in individuals with CAD regardless of diabetes mellitus status.”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [126]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Two RCTs have reported a beneficial effect on clinical endpoints in ASCVD patients without FH [119,120].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The mAb PCSK9 inhibitors evolocumab and alirocumab lower LDLC levels by ∼60% and, when added to statin therapy, decrease the risk of major vascular events [119].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the FOURIER trial, which included 27 564 patients with atherosclerotic CV disease, the addition of evolocumab to statin therapy (69% high-intensity therapy) resulted in a 15% relative risk reduction of the composite primary endpoint throughout a 2.2 year follow-up.”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, the best evidence to support lower LDL cholesterol targets in people with diabetes and established cardiovascular disease derives from multiple large randomized trials investigating the benefi ts of adding nonstatin agents to statin therapy.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [110]
Experimental — accuracy not yet measured
32 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Patients, Trial Regimen, and Follow-up
“In China, 613 patients underwent randomization from May 2016 through February 2017.”
§ Statistical Analysis
“In China, 614 patients underwent randomization after random assignment of the main trial cohort had been completed”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“| Missing data | 19 (<0.1) | 12 (<0.1) |”
Reported 0.1 · recomputed 0.200803
Citations
Cites
Ibanez, B., James, S., Agewall, S., Antunes, M. J., Bucciarelli-Ducci, C., Bueno, H., Caforio, A. L. P., Crea, F., Goudevenos, J. A., Halvorsen, S., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx393 · Cited by 9,728
Self-citationRoffi, M., Patrono, C., Collet, J.-P., Mueller, C., Valgimigli, M., Andreotti, F., Bax, J. J., Borger, M. A., Brotons, C., Chew, D. P., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv320 · Cited by 8,261
Self-citationEvolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Self-citation2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
Amsterdam, E. A., Wenger, N. K., Brindis, R. G., Casey, D. E., Ganiats, T. G., Holmes, D. R., Jaffe, A. S., Jneid, H., Kelly, R. F., Kontos, M. C., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.09.017 · Cited by 3,595
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., et al. (2003) · Nature Genetics · doi:10.1038/ng1161 · Cited by 2,985
2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction
O'Gara, P. T., Kushner, F. G., Ascheim, D. D., Casey, D. E., Chung, M. K., de Lemos, J. A., Ettinger, S. M., Fang, J. C., Fesmire, F. M., Franklin, B. A., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.11.019 · Cited by 2,625
Schwartz, G. G. (2001) · JAMA · doi:10.1001/jama.285.13.1711 · Cited by 2,499
Self-citation
Cited by
Items 1,301–1,400 of 3,636
Chinese Expert Consensus on the Clinical Diagnosis and Management of Statin Intolerance
Li, J., Dou, K., Zhou, Z., Zhao, D. H., Ye, P., Chen, H., Chen, Z., Peng, D., Guo, Y., Wu, N., et al. (2024) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3213 · Cited by 13
“68,69 In the IMPROVE-IT study, combine ezetimibe with statin similarly reduced MACE, although to a lesser extent.”
An Update on Dyslipidemia Management and Medications: A Review
Taher, Z. A., Taher, A. A., & Radi, S. (2024) · Cureus · doi:10.7759/cureus.56255 · Cited by 21
Papantoniou, E., Arvanitakis, K., Markakis, K., Papadakos, S. P., Tsachouridou, Ο., Popovic, D. S., Koufakis, T., Germanidis, G. S., & Kotsa, K. (2024) · Life · doi:10.3390/life14040449 · Cited by 19
“…guidelines included both evolocumab and alirocumab, with their safety and efficacy already having been extensively documented in the FOURIER and ODYSSEY studies for the general population, with no drug interactions having been reported, data are only available for evolocumab in PLHIV [194,195].”
BackgroundKim, H. K., Ryoo, S., Lee, S. H., Hwang, D., Choi, K. H., Park, J., Lee, H., Yoon, C., Lee, J. H., Hahn, J., et al. (2024) · Korean Circulation Journal · doi:10.4070/kcj.2024.0257 · Cited by 13
Schlegel, M., Cyr, Y., Newman, A. A. C., Schreyer, K. F., Durán, J. G. B., Sharma, M., Bozal, F. K., Gourvest, M., Forest, M. L., Afonso, M. S., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2412690121 · Cited by 12
Schwartz, G. G., Szarek, M. J., Jukema, J. W., Cobbaert, C. M., Reijnders, E., Bittner, V., Schwertfeger, M., Bhatt, D. L., Fazio, S., Garon, G., et al. (2025) · Diabetes Care · doi:10.2337/dc24-2110 · Cited by 17
Self-citationRen, J., Zhang, H., Shao, X., Gu, T., Hu, S., Zhang, Y., Jiang, C. Q., Zhang, J., Wu, X., Liu, X., et al. (2025) · International Journal of Cardiology · doi:10.1016/j.ijcard.2025.133352 · Cited by 14
McCarthy, C. P., Ballantyne, C. M., Blankstein, R., Budoff, M. J., Ditmarsch, M., Gibson, C. M., Kastelein, J. J. P., Návar, A. M., Nicholls, S. J., Ray, K. K., et al. (2025) · American Heart Journal · doi:10.1016/j.ahj.2025.07.012 · Cited by 12
Virani, S. S., Akeroyd, J. M., Nambi, V., Michos, E. D., Morris, P. B., Nasir, K., Smith, S. C., Stone, N. J., Petersen, L. A., & Ballantyne, C. M. (2019) · Circulation · doi:10.1161/circulationaha.118.034993 · Cited by 12
Is There a Need to Revise Goals in the Management of Dyslipidemias?
Sinning, D., & Landmesser, U. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1128-6 · Cited by 12
Annemans, L., Stock, J. K., & Chapman, M. J. (2019) · Journal of clinical lipidology · doi:10.1016/j.jacl.2019.07.005 · Cited by 13
Muthuramu, I., Mishra, M., Aboumsallem, J. P., Postnov, A. A., Gheysens, O. S., & Geest, B. D. (2019) · Aging · doi:10.18632/aging.102218 · Cited by 13
Implications for REDUCE IT in clinical practice
Bittner, V. (2019) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2019.11.003 · Cited by 13
Self-citationRomanelli, R. J., Ito, M. K., Karalis, D. G., Huang, H., Iorga, Ş. R., Kam, I. W., Thompson, S., & Azar, K. M. J. (2020) · Journal of clinical lipidology · doi:10.1016/j.jacl.2020.03.006 · Cited by 16
Advances in Clinical Cardiology 2019: A Summary of Key Clinical Trials
Linden, K., Mailey, J. A., Kearney, A., & Menown, I. B. A. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01355-5 · Cited by 13
Jia, X., Rifai, M. A., Liu, J., Agarwala, A., Gulati, M., & Virani, S. S. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00856-6 · Cited by 12
Gencer, B., & Giugliano, R. P. (2020) · Clinical Cardiology · doi:10.1002/clc.23410 · Cited by 18
“PCSK9 inhibitors in the US guidelines included cost considerations and a dedicated cost-effectiveness analysis for the US population 1 in addition to the scientific evidence from the large clinical trials.(9,10)”
BackgroundMethodInfluentialInterpreting the results of the VERTIS‐CV trial: Is this the end of the “class effect” perspective?
Koufakis, T., Παπάνας, Ν., Dimitriadis, G., Zebekakis, P. E., & Kotsa, K. (2020) · Journal of Diabetes · doi:10.1111/1753-0407.13105 · Cited by 12
Zeller, M., Lambert, G. C., Farnier, M., Maza, M., Nativel, B., Rochette, L., Vergely, C., & Cottin, Y. (2020) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2020.11.010 · Cited by 14
Tombling, B. J., Lammi, C., Bollati, C., Anoldi, A., Craik, D. J., & Wang, C. K. L. (2021) · ChemBioChem · doi:10.1002/cbic.202100103 · Cited by 12
Liang, Z., Chen, Q., Wei, R.-Q., Ma, C., Zhang, X., Xue, C., Fang, F., & Zhao, Q. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.648244 · Cited by 15
“And we did not perform subgroup analyses in patients with baseline LDL-C level over or below 100 mg/dL for the above reason, just as a significant difference of therapeutic effect reported in ODYSSEY OUTCOMES trial.”
BackgroundMethodInfluentialGoyal, A., Schibler, T., Alhanti, B., Hannan, K. L., Granger, C. B., Blazing, M. A., Lópes, R. D., Alexander, J. H., Peterson, E. D., Rao, S. V., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.17963 · Cited by 12
Self-citationPCSK9 Inhibition-Based Therapeutic Approaches: An Immunotherapy Perspective
Momtazi‐Borojeni, A. A., Pirro, M., Xu, S., & Sahebkar, A. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867328666211027125245 · Cited by 12
PCSK9 as a New Player in Cancer: New Opportunity or Red Herring?
Bonaventura, A., Vecchié, A., Ruscica, M., Grossi, F., & Dentali, F. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867328666211115122324 · Cited by 12
Therapeutic application of genome editing in dyslipidemia
Whittaker, M. N., & Musunuru, K. (2021) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000805 · Cited by 12
Levintow, S. N., Orroth, K. K., Breskin, A., Park, A. S., Flores‐Arredondo, J. H., Dluzniewski, P. J., Návar, A. M., Sørensen, H. T., & Brookhart, M. A. (2021) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.5396 · Cited by 13
“In clinical trials, adding PCSK9i to a statin (compared to statin monotherapy) reduced the risk of myocardial infarction (MI), ischemic stroke (IS), and other ASCVD events.(4,5) However, little is known about the real-world effectiveness of PCSK9i in improving cardiovascular outcomes outside of clinical trial settings…”
BackgroundDrug Treatment of Hypercholesterolemia in Older Adults: Focus on Newer Agents
Stoll, F., Eidam, A., Michael, L., Bauer, J. M., & Haefeli, W. E. (2022) · Drugs & Aging · doi:10.1007/s40266-022-00928-z · Cited by 14
“The clinical benefit of alirocumab in LDL-C reduction in older patients was also examined in a prespecified analysis of ODYSSEY OUTCOMES, evaluating cardiovascular outcomes after an acute coronary syndrome [14, 17].”
BackgroundMethodOptimal cardiovascular medical therapy: current guidelines and new developments
Reed, S., Dhir, N., & Widmer, R. J. (2022) · Baylor University Medical Center Proceedings · doi:10.1080/08998280.2022.2083903 · Cited by 15
“Outcomes revealed a reduction in ischemic events, including all-cause mortality and MI, compared to placebo in patients with an ACS event within the prior 1 to 12 months before therapy.(15) The addition of PCSK9 inhibitors to high-intensity statin therapy has been recommended in order to achieve lower LDL goals of 70…”
A Decade On: The Evolving Renaissance in Intracranial Atherosclerotic Disease
Beaman, C. B., Yaghi, S. R., & Liebeskind, D. S. (2022) · Stroke Vascular and Interventional Neurology · doi:10.1161/svin.122.000497 · Cited by 13
“28,29 One small, ongoing clinical trial in China (https:// clinicaltrials.gov/ct2/show/NCT05001984) plans to enroll 60 patients and assess the addition of a pro-protein convertase subtilisin-kexin type 9 inhibitor, alirocumab, to high-intensity statin and antiplatelet therapy to determine if it…”
Park, J., Lee, S., Hong, B., Cho, Y., Shin, W., Lim, S., Kang, W. C., Park, Y., Lee, S.-Y., Lee, Y., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.101933 · Cited by 14
Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition: The Big Step Forward in Lipid Control
Rikhi, R. R., & Shapiro, M. D. (2023) · European Cardiology Review · doi:10.15420/ecr.2023.14 · Cited by 13
Expanding the therapeutic landscape: ezetimibe as non-statin therapy for dyslipidemia
Lee, J., & Lee, S. (2023) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2023.243 · Cited by 17
Pharmacological Management of Diabetic Nephropathy
Papademetriou, V., Alataki, S., Stavropoulos, K., Papadopoulos, C. E., Bakogiannis, K., & Tsioufis, K. (2019) · Current Vascular Pharmacology · doi:10.2174/1570161117666190405164749 · Cited by 14
The Future of Lipid-Lowering Therapy
Zwol, W. H.-V., Rimbert, A., & Kuivenhoven, J. A. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8071085 · Cited by 14
“Monoclonal antibodies against proprotein convertase subtilisin/kexin type 9 (PCSK9) reduce LDL cholesterol with 51% on top of statins or as monotherapy with an additional risk reduction of 15% [5,6].”
BackgroundBoffa, M. B., & Koschinsky, M. L. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000641 · Cited by 15
Time‐Dependent Cardiovascular Treatment Benefit Model for Lipid‐Lowering Therapies
Khan, I., Peterson, E. D., Cannon, C. P., Sedita, L. E., Edelberg, J. M., & Ray, K. K. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.120.016506 · Cited by 10
“Figure 1 25– 46 depicts a comparison of”
InfluentialSelf-citationLow‐density lipoprotein cholesterol lowering in real‐world patients treated with evolocumab
Desai, N. R., Wade, R. L., Xiang, P., Pinto, L. A., Nunna, S., Wang, X., Exter, J., Mues, K. E., Habib, M., & Chen, C. (2021) · Clinical Cardiology · doi:10.1002/clc.23600 · Cited by 13
Arai, H., Bujo, H., Masuda, D., Ishibashi, T., Nakagawa, S., Tanabe, K., Kagimura, T., Kang, H., Kim, M. H., Sung, J., et al. (2021) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.62821 · Cited by 14
Advances in Clinical Cardiology 2020: A Summary of Key Clinical Trials
Kearney, A., Linden, K., Savage, P., & Menown, I. B. A. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01711-z · Cited by 14
Drexel, H., Pocock, S., Lewis, B. S., Saely, C. H., Kaski, J. C., Rosano, G. M. C., Tautermann, G., Huber, K., Dopheide, J. F., MADER, A., et al. (2021) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvab048 · Cited by 12
Coelho‐Lima, J., Georgiopoulos, G. A., Ahmed, J., Adil, S. E. R., Gaskin, D., Bakogiannis, C., Sopova, K., Ahmed, F., Ahmed, H., Spray, L., et al. (2021) · Heart · doi:10.1136/heartjnl-2021-319225 · Cited by 13
Statin Intolerance and Noncompliance: An Empiric Approach
Grundy, S. M., & Vega, G. L. (2021) · The American Journal of Medicine · doi:10.1016/j.amjmed.2021.09.014 · Cited by 15
Efficacy and Safety of PCSK9 Monoclonal Antibodies in Patients With Diabetes
Marouf, B. H., Iqbal, Z., Mohamad, J. B., Bashir, B., Schofield, J. D., Syed, A. A., Kilpatrick, E. S., Stefanutti, C., & Soran, H. (2022) · Clinical Therapeutics · doi:10.1016/j.clinthera.2021.12.005 · Cited by 12
Kristensen, A. M. D., Pareek, M., Kragholm, K. H., Sehested, T. S. G., Olsen, M. H., & Prescott, E. (2022) · Cardiology · doi:10.1159/000524948 · Cited by 18
Adaptive Context Based Sequential Prediction For Lossless Audio Compression
Giurcăneanu, C. D., Tabus, I., & Astola, J. T. (1998) · doi:10.5281/zenodo.36822 · Cited by 12
Bjerre, K. P., Clemmensen, T. S., Poulsen, S. H., Hvas, A., Holm, N. R., Grove, E. L., Bouchelouche, K., Kristensen, S. D., & Eiskjær, H. (2020) · Clinical Transplantation · doi:10.1111/ctr.14133 · Cited by 11
Mansoor, T., Rao, B. H., Gupta, K., Parikh, S. S., Abramov, D., Mehta, A., Al Rifai, M., Virani, S. S., Nambi, V., Minhas, A. M. K., et al. (2025) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-024-00712-x · Cited by 12
“Impor-tantly, although LDL-C reduction is similar between PCSK9 inhibitors and inclisiran, PCSK9 monoclonal antibodies have demonstrated benefits in cardiovascular outcomes [29, 30], while phase 3 trials investigating inclisiran’s cardiovascular outcome benefits are still ongoing.”
InfluentialInflammation reprogramming and immunomodulation: Next-generation treatments for atherosclerosis
Choudhury, R. P., Hargreaves, R., Chai, J., & Fisher, E. A. A. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102288 · Cited by 15
Cordero, A., Santos‐Gallego, C. G., Manzanas, A. O., Rodríguez‐Mañero, M., Fernández-Olmo, R., & Quesada, A. J. (2025) · European Cardiology Review · doi:10.15420/ecr.2025.16 · Cited by 11
“8,9 We performed a meta-analysis with all the trials available that reported significant reduction in MI and stroke.”
Sun, H., Li, Z., Song, X., Liu, H., Li, Y., Hao, Y., Teng, T., Liu, J., Liu, J., Zhao, D. H., et al. (2021) · European Heart Journal Acute Cardiovascular Care · doi:10.1093/ehjacc/zuab053 · Cited by 12
Nakao, S., Ishihara, T., Tsujimura, T., Iida, O., Hata, Y., Toyoshima, T., Higashino, N., & Mano, T. (2021) · Journal of Cardiology · doi:10.1016/j.jjcc.2021.10.005 · Cited by 12
Cowie, M., Bozkurt, B., Butler, J., Briggs, A. H., Kubin, M., Jonas, A., Adler, A., Patrick‐Lake, B., & Zannad, F. M. (2022) · International Journal of Cardiology · doi:10.1016/j.ijcard.2022.07.020 · Cited by 12
2022 Consensus Statement on the Management of Familial Hypercholesterolemia in Korea
Lee, C. J., Yoon, M., Kang, H., Kim, B. J., Choi, S. H., Jeong, I., Lee, S., & on behalf of Task Force Team for Familial Hypercholesterolemia, K. S. O. L. A. A. (2022) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2022.11.3.213 · Cited by 12
Zhao, Z.-W., Liu, C., Zhao, Q., Xu, Y.-K., Cheng, Y., Sun, T., & Zhou, Y. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1019233 · Cited by 12
“The major findings are as follows: (1) there was a close association between TyG index and highrisk plaque characteristics; (2) TyG index remained to be independently and robustly associated with high-risk plaques including TCFA and ruptured plaque with the adjustment of various multivariate models, despite being take…”
BackgroundMethodResultLuo, J., Liao, W., Wang, X., Xu, R., Li, W., Li, W., Liu, K., Huang, K., Ma, Y., Wang, T., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-062046 · Cited by 13
Effects of PCSK9 inhibitors on metabolic-associated fatty liver disease: a short review
Jakielska, E., Głuszak, P., Walczak, M., & Bryl, W. (2023) · Gastroenterology Review · doi:10.5114/pg.2023.126054 · Cited by 13
“This led to FDA approval of the treatment [11, 12].”
BackgroundLiu, T., Zhao, D., Wang, M., Sun, J., Liu, J., Li, J., Duan, Y., Hu, P., Sun, Z., Liu, J., et al. (2023) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.63937 · Cited by 11
Relationship between lipoprotein(a) and colorectal cancer among inpatients: a retrospective study
Wang, H., Zheng, H., Meng, P., Cao, X., Liu, J., Zhang, T., Zuo, H., & Wang, Z. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1181508 · Cited by 12
Giglio, R. V., Muzurović, E. M., Patti, A. M., Toth, P. P., Agarwal, M. A., Almahmeed, W. A., Klisic, A. N., Ciaccio, M., & Rizzo, M. (2023) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484231186855 · Cited by 12
Ueki, Y., Häner, J. D., Losdat, S., Gargiulo, G., Shibutani, H., Bär, S., Otsuka, T., Kavaliauskaite, R., Mitter, V. R., Temperli, F., et al. (2023) · Thrombosis and Haemostasis · doi:10.1055/a-2156-7872 · Cited by 12
Do Triglyceride-Rich Lipoproteins Equal Low-Density Lipoproteins in Risk of ASCVD?
Wadström, B. N., Wulff, A. B., Pedersen, K. M., & Nordestgaard, B. G. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01153-8 · Cited by 13
“However, results were inconsistent and instead, other randomized controlled trials showed that proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, which mainly lower LDL cholesterol, additionally decrease risk of ASCVD on top of statins [8, 9].”
ResultPan, L., Jiang, W., Liao, L., Li, W., & Wang, F. (2024) · Coronary Artery Disease · doi:10.1097/mca.0000000000001320 · Cited by 11
Piras, L., Zuccanti, M., Russo, P., Riccio, F., Agresti, A., Lustri, C., Dardani, D., Ferrera, A., Fiorentini, V., Tocci, G., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052502 · Cited by 12
“PCSK9 inhibitors have been found to reduce LDL cholesterol levels and decrease ASCVD independently of cholesterol reduction [84,85].”
BackgroundFiolet, A. T. L., Keusters, W. R., Blokzijl, J., Nidorf, S. M., Eikelboom, J. W., Budgeon, C. A., Tijssen, J. G. P., Römer, T. J., Westendorp, I. C. D., Cornel, J. H., et al. (2024) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcae021 · Cited by 11
Rosenson, R. S., Tate, A., Mar, P., Grushko, O. G., Chen, Q., & Goonewardena, S. N. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.117529 · Cited by 14
Medical Therapy for Peripheral Artery Disease
Canonico, M. E., Hess, C. N., Rogers, R. K., & Bonaca, M. P. (2024) · Current Cardiology Reports · doi:10.1007/s11886-024-02065-y · Cited by 14
“Moreover, alirocumab reduced limb events such as CLTI, LER and amputation by 31% [43].”
The Role of Lipoprotein(a) in Peripheral Artery Disease
Pavlatos, N., & Kalra, D. K. (2024) · Biomedicines · doi:10.3390/biomedicines12061229 · Cited by 17
“The only adverse event which was statistically significant from placebo in both alirocumab and evolocumab was injection sight reaction which was seen at a rate of 3.8% and 2.1%, respectively [80,82].”
BackgroundResultInfluentialPCSK9 and Coronary Artery Plaque—New Opportunity or Red Herring?
Barbieri, L., Tumminello, G., Fichtner, I., Corsini, A., Santos, R. D., Carugo, S., & Ruscica, M. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01230-6 · Cited by 15
“Along with the undeniable clinical cardiovascular benefit of adding PCSK9 inhibitors to a standard lipid-lowering therapy [79, 80], new imaging approaches have allowed us to characterize the impact of these agents on coronary atherosclerosis [81], highlighting the relationship between achieved LDLc…”
BackgroundLipids and Inflammation: Novel Molecular Targets and Therapeutic Implications
Triglia, L. T., Gurgoglione, F. L., Barocelli, F., Bianconcini, M., & Niccoli, G. (2024) · Current Medicinal Chemistry · doi:10.2174/0109298673311105240902053715 · Cited by 12
Engebretsen, I., Ødegaard, K. M., Halvorsen, S., Bugge, C., Kristiansen, I. S., Støvring, H., & Munkhaugen, J. (2024) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcae099 · Cited by 12
Colchicine: Repositioning an “ancient” medicine in the 21st century
Nasonov, E. L., & Drapkina, O. M. (2024) · Rheumatology Science and Practice · doi:10.47360/1995-4484-2024-445-464 · Cited by 12
Achieving More Optimal Lipid Control with Non-Statin Lipid Lowering Therapy
Nicholls, S. J., & Nelson, A. J. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01280-4 · Cited by 13
Lee, M., Lee, K. J., Kim, J., Lee, D. Y., Park, R. W., Rhee, S. Y., Cha, J. M., Yang, H., Jang, J., Jung, S., et al. (2025) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2024-334708 · Cited by 18
Lipid-Lowering Therapy and Cardiovascular Prevention in Elderly
Baratta, F., Moscucci, F., Lospinuso, I., Cocomello, N., Colantoni, A., Costanzo, A. D., Tramontano, D., D’Erasmo, L., Pastori, D., Ettorre, E., et al. (2025) · Drugs · doi:10.1007/s40265-025-02182-0 · Cited by 13
“Subanalyses of both alirocumab (Odissey outcome) [74] and evolocumab (Fourier) [75] phase 3 studies were conducted by dividing patients using 65 years as the cutoff age.”
Jianu, N., Nițu, E.-T., Merlan, C., Nour, A., Buda, S., Suciu, M., Luca, S. A., Sbârcea, L., Andor, M., & Buda, V. O. (2025) · Pharmaceuticals · doi:10.3390/ph18081150 · Cited by 20
“As evidence from long-term studies accumulates, PCSK9 inhibitors continue to redefine the therapeutic landscape of lipid disorders, especially in FH and statin-intolerant populations [25].”
InfluentialMasana, L., & Plana, N. (2019) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2019.04.005 · Cited by 15
Li, H., Wei, Y., Yang, Z., Zhang, S., Xu, X., Shuai, M., Vitse, O., Wu, Y., Baccara‐Dinet, M. T., Zhang, Y., et al. (2020) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-020-00394-1 · Cited by 13
Liu, J., Shao, P. P., Guiadeen, D., Krikorian, A. D., Sun, W., Deng, Q., Cumiskey, A.-M., Duffy, R. A., Murphy, B. A., Mitra, K., et al. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2020.127668 · Cited by 11
Wang, X., Pei, J., Zheng, K., & Hu, X. (2021) · Clinical Cardiology · doi:10.1002/clc.23606 · Cited by 13
“Subsequent studies, including the IMPROVE-IT, FOURIER, and ODYSSEY OUTCOMES trials, have confirmed that a decrease in the absolute value of LDL-C will result in a decrease in ASCVD endpoint events.(30-32) In a study involving 27 533 women with an average follow-up period of 17.”
Hagström, E., Vilela, F. S., Svensson, M. K. E., Hallberg, S., Söreskog, E., & Villa, G. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01852-1 · Cited by 14
National Asthma Education and Prevention Program 2020 Guidelines: What’s Important for Primary Care
Murphy, M. (2021) · The Journal of Family Practice · doi:10.12788/jfp.0219 · Cited by 16
The Impact of the COVID-19 Outbreak on Patients’ Adherence to PCSK9 Inhibitors Therapy
Caso, V. M., Sperlongano, S., Liccardo, B., Romeo, E., Padula, S., Arenga, F., D’Andrea, A., Caso, P., Golino, P., Nigro, G., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11030475 · Cited by 11
Relationship between PCSK9 and endothelial function in patients with acute myocardial infarction
Cimaglia, P., Fortini, F., Sega, F. V. D., Cardelli, L. S., Massafra, R. F., Morelli, C., Trichilo, M., Ferrari, R., Rizzo, P., & Campo, G. C. (2022) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2022.06.020 · Cited by 12
Wang, Z., Bao, Q., Song, X., Song, H., Wei, S., Lv, J., Wang, F., & An, J. (2022) · Cardiovascular Innovations and Applications · doi:10.15212/cvia.2022.0011 · Cited by 11
Mehta, V., Puri, R., Duell, P. B., Iyengar, S. S., Wong, N. D., Yusuf, J., Mukhopadhyay, S., Pradhan, A., Muruganathan, A., WANGNOO, S. K., et al. (2022) · Journal of the Association of Physicians of India · doi:10.5005/japi-11001-0099 · Cited by 16
Milosavljević, M. N., Stefanović, S., & Pejčić, A. V. (2023) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001429 · Cited by 11
Remnant cholesterol, vascular risk, and prevention of atherosclerosis
Pintó, X., Fanlo‐Maresma, M., Esteve-Luque, V., & Millán, J. (2023) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2023.07.005 · Cited by 18
van Veelen, A., Küçük, I. T., Fuentes, F. H., Kahsay, Y. A., García‐García, H. M., Delewi, R., Beijk, M. A. M., den Hartog, A. W., Grundeken, M. J., Vis, M. M., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12185807 · Cited by 12
“Several studies have investigated the effect of aggressive lipid lowering with statins and proprotein convertase subtilisin kexin type 9 (PCSK9 inhibitors) on plaque stabilization and, more extensively, on clinical outcomes [25,26].”
BackgroundGiordano, S. A., Franchi, F., Rollini, F., Saleh, T. A., Uzunoglu, E. C., Costa, F., Angiolillo, D. J., & Ortega‐Paz, L. (2023) · Minerva Cardiology and Angiology · doi:10.23736/s2724-5683.23.06411-6 · Cited by 11
Effects of a stepwise, structured LDL-C lowering strategy in patients post-acute coronary syndrome
Khader, A. O., Trier, T. J. V., van der Brug, S., Liem, A. H., Groenemeijer, B. E., Schut, A., Jorstad, H. T., Martens, F. M. A. C., & Alings, M. (2024) · Netherlands Heart Journal · doi:10.1007/s12471-023-01851-7 · Cited by 15
Secondary prevention of cardiovascular diseases: current state of the art
Hasenfuss, G. P. (2018) · Kardiologia Polska · doi:10.5603/kp.a2018.0198 · Cited by 14
PCSK9: from molecular biology to clinical applications
Malo, J., Parajuli, A., & Walker, S. W. (2019) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/0004563219864379 · Cited by 12
Pallazola, V. A., Sathiyakumar, V., Ogunmoroti, O., Fashanu, O. E., Jones, S. R., Santos, R. D., Toth, P. P., Bittencourt, M. S., Duncan, B. B., Lotufo, P. A., et al. (2019) · Journal of clinical lipidology · doi:10.1016/j.jacl.2019.07.002 · Cited by 11
Nishikido, T., & Ray, K. K. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14851 · Cited by 13
“C levels≥1.8 mmol·L−1 despite receiving intensive or maximally tolerated statin therapy (Schwartz et al., 2018).”
BackgroundInfluentialReducing residual cardiovascular risk with novel therapies
Davidson, M. H. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000672 · Cited by 12
“The IMPROVE-IT [3], FOURIER [4], ODYSSEY-OUTCOMES [5] and REVEAL [6] trials have documented that multiple nonstatin therapies, ezetimibe, evolocumab, alirocumab and anacetrapib, respectively, in combination with optimal statins further reduce MACE in proportion to the decrease in nonHDL-C.”
MethodTada, H., Okada, H., Nomura, A., Nohara, A., Takamura, M., & Kawashiri, M. (2020) · Internal Medicine · doi:10.2169/internalmedicine.3737-19 · Cited by 11
“These observations motivated us to develop medications mimicking these mutations in order to reduce the LDL cholesterol levels (5-8).”
BackgroundWarden, B. A., Purnell, J. Q., Duell, P. B., Craigan, C., Osborn, D., Cabot, E., & Fazio, S. (2021) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2020.100144 · Cited by 14
Lipid Optimization in Lower Extremity Peripheral Arterial Disease
Sucharitkul, P. P. J., Jones, K. L., Scott, D. J. A., & Bailey, M. A. (2021) · Annals of Vascular Surgery · doi:10.1016/j.avsg.2021.03.055 · Cited by 12
Ponte-Negretti, C. I., Wyss, F., Piskorz, D. L., Santos, R. D., Villar, R., Lorenzatti, A., López-Jaramillo, P. A., Toth, P. P., Amaro, A. J. J., Rodrigo, A. K., et al. (2021) · Archivos de cardiología de México · doi:10.24875/acm.21000005 · Cited by 31
Wang, W. “., Feng, Z., & Bai, J. (2021) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2203093 · Cited by 11
“Randomized controlled trial (RCT) data fromODYSSEY results indicate that alirocumab has significant clinical benefits in subjects at high CV risk [9].”
BackgroundMethodInfluential
Metadata
- Authors
- Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., Jukema, J. W., Lecorps, G., Mahaffey, K. W., Moryusef, A., Pordy, R., Quintero, K., Roe, M. T., Sasiela, W. J., Tamby, J.-F., Tricoci, P., White, H. D., & Zeiher, A. M.
- Affiliations
- Inserm (FR)
- From the Division of Cardiology, University of Colorado School of Medicine, Aurora (G.G.S.); Assistance Publique–Hôpitaux de Paris, Hôpital Bichat, Paris Diderot University, Sorbonne Paris Cité, FACT (French Alliance for Cardiovascular Trials), and INSERM Unité 1148 (P.G.S.), and Sanofi (C.H., G.L.) — all in Paris; the National Heart and Lung Institute, Imperial College, Royal Brompton Hospital, London (P.G.S.); the State University of New York Downstate School of Public Health, Brooklyn (M.S.), and...
- State University of New York (US)
- Brigham and Women's Hospital (US)
- St. Michael's Hospital (CA)
- Goethe University Frankfurt (DE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-11-29
- Volume
- 379
- Issue
- 22
- Pages
- 2097-2107
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2899997727
- Semantic Scholar
- 3bd18f4d47c498a70a737151f3b2a9a1a09050bd
- Cited by
- 3,634
- References
- 22
- Citations by year
- 2026: 452 · 2025: 403 · 2024: 450 · 2023: 446 · 2022: 471 · 2021: 473 · 2020: 481 · 2019: 414 · 2018: 31
- FWCI
- 363.89
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- SZTE Publicatio Repozitórium (University of Szeged) (acceptedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Leiden Repository (Leiden University) (submittedVersion)
- Lanzhou University Institutional Repository (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- HAL (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Institutional Repositories DataBase (IRDB) (submittedVersion, cc-by-nc-nd)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Lirias (submittedVersion)
- Dspace Repository (Marmara Üniversitesi) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Griffith Research Online (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Sanofi
- Regeneron Pharmaceuticals
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Keywords
- alirocumab, PCSK9 inhibitors, acute coronary syndrome, cardiovascular outcomes, LDL cholesterol lowering, high-intensity statin therapy, LDL cholesterol targets, cardiovascular mortality, myocardial infarction, ischemic stroke, unstable angina, apolipoprotein B, non-HDL cholesterol, secondary prevention, cardiovascular risk reduction, LDL-C lowering therapy
- MeSH terms
- Proprotein Convertase 9, PCSK9 Inhibitors, Adult, Aged, Antibodies, Monoclonal, Anticholesteremic Agents, Cardiovascular Diseases, Double-Blind Method, Female, Follow-Up Studies, Humans, Hypercholesterolemia, Cholesterol, LDL, Male, Middle Aged, Acute Coronary Syndrome, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-08, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-08 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

